In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Summary

Optical coherence tomography (OCT) is a high resolution imaging technique that allows analysis of tissue specific optical properties providing the means for tissue differentiation. We developed needle based OCT, providing real-time imaging combined with on-the-spot tumor differentiation. This publication describes a method for percutaneous, needle based OCT of renal masses.

Abstract

Optical coherence tomography (OCT) is the optical equivalent of ultrasound imaging, based on the backscattering of near infrared light. OCT provides real time images with a 15 µm axial resolution at an effective tissue penetration of 2-3 mm. Within the OCT images the loss of signal intensity per millimeter of tissue penetration, the attenuation coefficient, is calculated. The attenuation coefficient is a tissue specific property, providing a quantitative parameter for tissue differentiation.

Until now, renal mass treatment decisions have been made primarily on the basis of MRI and CT imaging characteristics, age and comorbidity. However these parameters and diagnostic methods lack the finesse to truly detect the malignant potential of a renal mass. A successful core biopsy or fine needle aspiration provides objective tumor differentiation with both sensitivity and specificity in the range of 95-100%. However, a non-diagnostic rate of 10-20% overall, and even up to 30% in SRMs, is to be expected, delaying the diagnostic process due to the frequent necessity for additional biopsy procedures.

We aim to develop OCT into an optical biopsy, providing real-time imaging combined with on-the-spot tumor differentiation. This publication provides a detailed step-by-step approach for percutaneous, needle based, OCT of renal masses.

Introduction

The past decades have shown a steady increase in the incidence of renal masses ^1,2. Until now, renal mass treatment decisions have been made primarily on the basis of MRI and CT imaging characteristics, age and comorbidity. However these diagnostic methods and clinical parameters lack the finesse to truly detect the malignant potential of a renal mass. A core biopsy or fine needle aspiration with sufficient tissue for pathological evaluation (diagnostic) provides objective tumor differentiation with both sensitivity and specificity in the range of 95-100% ³. Therefore biopsy is gaining acceptance in the evaluation of suspicious renal masses ^4,5. However, biopsies without sufficient tissue to establish a diagnosis or with normal renal parenchyma (non-diagnostic) occur at a rate of 10-20% overall, and even up to 30% in small renal masses (<4 cm, SRMs), delaying the diagnostic process due to the frequent necessity for additional biopsy procedures^3,5.

Optical coherence tomography (OCT) is a novel imaging modality that has the potential to overcome the aforementioned hurdles in renal mass differentiation. Based on the backscattering of near infrared light, OCT provides images with a 15 µm axial resolution at an effective tissue penetration of 2-3 mm (Figure 1, 2). The loss of signal intensity per millimeter of tissue penetration, a resultant of tissue-specific light scattering, is expressed as the attenuation coefficient (µ_OCT: mm^-1) as described by Faber et al. ⁶. Histological characteristics can be correlated to µ_OCT values providing a quantitative parameter for tissue differentiation (Figure 3).

During carcinogenesis, malignant cells display an increased number, larger and more irregularly shaped nuclei with a higher refractive index and more active mitochondria. Due to this overexpression of cell components, a change in μ_oct is to be expected when comparing malignant tumors to benign tumors or unaffected tissue ⁷.

Recently we studied the ability of superficial OCT to differentiate between benign and malignant renal masses ^8,9. In 16 patients, intra-operative OCT measurements of tumor tissue were obtained using an externally placed OCT probe. The control arm comprised of OCT measurements of unaffected tissue in the same patients. Normal tissue showed a significantly lower median attenuation coefficient compared to malignant tissue, confirming the potential of OCT for tumor differentiation. This quantitative analysis has been applied in a similar fashion to grade other types of malignant tissue, such as urothelial carcinoma ^10,11 and vulvar epithelial neoplasia differentiation ¹².

We aim to develop OCT into an optical biopsy, providing real-time imaging combined with on-the-spot tumor differentiation. The goal of the current study is to describe a percutaneous, needle based, OCT approach in patients diagnosed with a solid enhancing renal mass. This method description is, to our knowledge, the first to assess the possibility of needle based OCT of renal tumors.

Protocol

The presented procedure takes place under a research protocol approved by the Institutional Review Board of the Academic Medical Center Amsterdam, registration number NL41985.018. Written informed consent is required from all participants.

1. System

1. For this experiment, use a Fourier domain OCT system, operating at a 1,280–1,350 nm wavelength band ¹³. Fourier domain low-coherence interferometry allows for continuous scanning which increases the data acquisition speed when compared to the first generation time-domain OCT systems. Note: The OCT system is interfaced with a fiber optic probe, scanning helically at ~90° angle. It has an outer diameter of 2.7F (0.9 mm) and an insertable length of 135 cm. The probe connects to the OCT console through a drive motor and optical controller (mounting dock) with a pullback range of 54 mm. The acquired OCT datasets consist of 541 cross-sectional images (B-scans) with an axial resolution of 15 µm (Figure 1, 2).
2. To guarantee accurate and reproducible attenuation measurements, calibrate by measuring μ_oct for increasing concentrations based on weight percentage of a fat emulsion, (e.g., Intralipid) as described previously by Kodach et al.^{14, 15}.
   In short:
   1. Dilute a standard batch of 20% fat emulsion with demineralized H₂O to achieve concentrations of 0.125, 0.250, 0.5, 1.0, 2.0, 4.0, 10, 15 and 20 (stock) percent.
      1. Place the OCT probe in 200 ml of fat emulsion mixture and acquire an OCT measurement.
      2. Cross reference extracted μ_oct values with known values in literature.

2. Time Out and Patient Positioning

1. Prior to starting the procedure, perform a “time out” checking name, date of birth, procedure, procedural side, anticoagulant use, and allergies.
2. Depending on the tumor location, place the patient in either prone or lateral decubitus position. Provide the patient with adequate support and verify if he/she expects to be comfortable in this position over a 20 to 40 min period.
3. Using ultrasound (US)¹⁶, localize the tumor and mark the needle entry point on the skin with permanent ink.
   NOTE: When using computed tomography (CT), use a flexible needle guidance template to localize the preferred position of the access needle.

3. Disinfection and Sterile Draping

1. Put on a surgical cap and mouth cover.
2. Clean the skin around the puncture site using a chlorhexidine/alcohol solution, taking care not to remove the previously placed needle entry mark (step 2.3). Disinfecting a wide area will prevent the necessity for additional cleaning in case of unexpected access needle repositioning.
3. With regard of the sterile content, open the percutaneous puncture set containing: a 10 ml syringe, a blunt aspiration needle, a 21 G injection needle, a scalpel, a 15 G co-axial introducer needle, a 18 G trocar needle, and a 16 G core biopsy gun.
4. Wash hands thoroughly, applying hand disinfectant afterwards. Put on a surgical gown and sterile gloves.
5. Cover the patient in sterile drapes.
6. Apply a sterile cover around the ultrasound probe and fix the needle guide in place.

4. OCT Preparation

1. Start the OCT console and enter the patient details in the fields labeled patient ID, last name, first name and DOB (date of birth) using the console interface.
2. With regard of the sterile content, unpack the OCT package containing an OCT probe, a sterile mounting dock cover, and a 5 ml luer-lock syringe.
3. Apply the sterile cover to the OCT console mounting dock. Guiding the non-sterile mounting dock requires the help of an assistant.
4. Fill the 5 ml syringe with 0.9% NaCl and attach it to the flushing port. Flush the OCT probe until water appears in the distal part of the probe cover.
5. Load the OCT probe into the mounting dock. After loading the probe will rotate and emit red light confirming proper functioning. Leave the probe in its protective cover during flushing and loading to minimize the risk of damage.
6. Remove the OCT probe from its cover. Place the probe on a hard surface and use a scalpel to shorten the tip. Fix the distal part of the probe during cutting in order to minimize pressure on the optical fiber and prism. Cut 5 mm distal from prism, using the emitted (red) light for orientation.

5. Puncture

1. Anesthetize the skin and deep layers using 2% lidocaine (20 mg/ml). Wait several minutes allowing for the lidocaine to take effect. Ask the patient if there is any pain.
2. Using the needle guide, place the 15 G co-axial introducer needle verifying the position through imaging. If placement is satisfactory, remove the obturator (sharp needle core).
3. Place the 18 G trocar needle through the introducer needle, piercing the tumor. Again verify the position of the needle with imaging. If placement is satisfactory remove the obturator.
4. Feed the OCT probe up the trocar needle until feeling resistance.
5. While fixing the OCT probe, retract the trocar needle, exposing the OCT probe to the tumor tissue. Keeping the tip of the trocar needle within the tumor minimizes kinking of the OCT probe during breathing cycles. This lowers the risk of probe damage.
6. OCT Scan:
   1. Perform an OCT scan, with the console set at 541 B-scans per dataset. The OCT system used here will perform an automated pullback over a length of 5.4 cm requiring no specific parameter adjustments.
   2. Check the scan for quality, artefacts and the appearance of solid tissue (Figure 1A). Artefacts most commonly appear as circular bands standing out from the normal OCT pattern (Figure 1B).
   3. Replace the probe if artefacts persists after rescanning.
7. Repeat step 5.6 until a minimum of 3 OCT datasets are acquired.
8. Remove the OCT probe and trocar needle, leaving the introducer needle in-place.
9. Arm the core biopsy gun and place it through the introducer needle, verifying the position on imaging.
10. If the positioning is satisfactory, fire the biopsy gun.
11. Place biopsy material in container according to pathology department protocol. Here, place biopsies on a petri dish with a paper inlay, sufficiently saturated with 0.9% NaCl.
12. Check the core biopsy quality and repeat step 5.9 and 5.10 until sufficient material is obtained.

Results

Among the first 25 tumors (23 patients), a total of 24 successful OCT procedures were performed. In one case a probe malfunction led to the inability to acquire an OCT scan. Two adverse events (AE) occurred, which are described in detail in the discussion section. General patient characteristics are found in Table 1.

The OCT console has pre-installed software providing real-time OCT images for immediate qualitative analysis of acquired datasets. For further analysis and attenu...

Discussion

In this publication we report on the feasibility of percutaneous, needle based, OCT of the kidney. This is an essential first step in the development of OCT into a clinically applicable technique for tumor differentiation, termed as an “Optical Biopsy”. Our first 25 patients have shown percutaneous OCT to be an easy and safe procedure. An optical biopsy has two advantages over conventional core biopsies. First, the real time acquisition and analysis of OCT data will provide instant diagnostic results, compare...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
15 G/7.5 cm Co-Axial Introducer Needle	Angiotech, Gainesville, USA	MCXS1612SX
18 G/20 cm Trocar Needle	Cook medical, Bloomington, USA	DTN-18-20.0-U
16 G/20 cm Quick-Core Biopsy Gun	Cook Medical, Bloomington, USA	G07827
Ilumien Optis PCI Optimization System (OCT & FFR)	St. Jude medical, St. Paul, USA	C408650	Part of Dragonfly Kit. St. Jude medical, St. Paul, USA. (C4088643)
Dragonfly Duo Imaging Catheter	LightLab Imaging, Westford, USA	C408644	Part of Dragonfly Kit. St. Jude medical, St. Paul, USA. (C4088643)
Sterile Dock Cover	CFI Med. Solutions, Fenton, USA	200-700-00	Part of Dragonfly Kit. St. Jude medical, St. Paul, USA. (C4088643)
5 ml Luer-lock Syringe	Merit Med. Syst., South Jordan, USA	C408647
10 ml Syringe	BD, Franklin Lakes, USA	300912
18 G Blunt Fill Needle	BD, Franklin Lakes, USA	305180
21 G Injection Needle	BD, Franklin Lakes, USA	301155
Sterile scalpel	BD, Franklin Lakes, USA	372611
NaCl 0,9% solution	Braun, Melsungen AG, Germany	222434
Lidocaïne HCl 2% (20 mg/ml) solution	Braun, Melsungen AG, Germany	3624480
Sterile Ultrasound Gel, Aquasonic 100	Parker Lab. Inc., Fairfield, USA	GE424609
Sterile Ultrasound Cover	Microtek Med., Alpharetta, USA	PC1289EU
Pathology Container
AMIRA software package	FEI Visualization Sciences Group, Hillsboro, USA	Software platform for 3D data analysis
FIJI software package (open source)	Open source, http://fiji.sc/Fiji		Open source image processing software